Skip NavigationSkip to Content
Return Return to Search Results

Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection

  1. Author:
    Sei, S.
    Sandelli, S. L.
    Theofan, G.
    Ratto-Kim, S.
    Kumagai, M.
    Loomis-Price, L. D.
    Cox, J. H.
    Jarosinski, P.
    Walsek, C. M.
    Brouwers, P.
    Venzon, D. J.
    Xu, J.
    Pizzo, P. A.
    Moss, R. B.
    Robb, M. L.
    Wood, L. V.

  2. Author Address

    Sei S NCI, HIV Clin Interface Lab, SAIC Frederick, FCRDC,NIH Bldg 322,Rm 27B Frederick, MD 21702 USA NCI, HIV Clin Interface Lab, SAIC Frederick, FCRDC,NIH Frederick, MD 21702 USA NCI, HIV & AIDS Malignancy Branch, NIH Bethesda, MD 20892 USA NCI, Pediat Branch, NIH Bethesda, MD 20892 USA NCI, Biostat & Data Management Sect, NIH Bethesda, MD 20892 USA NIH, Dept Pharm, Ctr Clin Bethesda, MD 20892 USA NIH, Dept Nursing, Ctr Clin Bethesda, MD 20892 USA Henry M Jackson Fdn, HIV Lab Rockville, MD USA Walter Reed Army Inst Res, Dept Retrovirol Rockville, MD USA Immune Response Corp Carlsbad, CA USA Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res Boston, MA 02115 USA
    1. Year: 1999
  2. Journal: Journal of Infectious Diseases
    1. 180
    2. 3
    3. Pages: 626-640
  4. Type of Article: Article
  1. Abstract:

    The safety and preliminary activity of human immunodeficiency virus type 1 (HIV-1) immunogen were evaluated in 10 HIV-1-infected children with disease stage N1,2 or A1,2, Multiple inoculations of 2.5 or 10 units (U) of HIV-1 immunogen were safe and well tolerated without an acceleration of disease progression. When antiretroviral agents were coadministered, the 10 U dose appeared to be associated with more sustained reduction in plasma HIV-1 RNA than the 2.5 U dose (median log(10) HIV-1 RNA at month is, 3.07 vs. 4.01 copies/mL in 10 U [n = 4] vs. 2.5 U [n = 3], respectively; P =.034). Levels of regulated-on-activation, normal T cell-expressed and -secreted chemokine produced from HIV-1 immunogen-stimulated lymphocytes in vitro were increased in the children who had HIV-1 immunogen-specific antibody responses (P <.02) and appeared to be inversely correlated with levels of plasma HIV-1 RNA (P<.01). These preliminary data warrant larger studies to determine the effectiveness of adjunctive therapy with HIV-1 immunogen in children with HIV-1 infection. [References: 75]

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel